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Abstract
Introduction: Cancer is a major public health problem in the U.S. and the world. In 2013
there were an estimated 1,660,290 new cases of cancer in the U.S. Cancer-Cachexia (CC) is a
common effect of many cancers, and is directly responsible for 20-40% of cancer-related deaths.
The mechanisms that control the development of CC are not well understood. Most
investigations of CC focus on the post-cachectic state and do not examine the progression of the
condition. The purpose of this study was to utilize RNA sequencing to analyze transcriptomic
alterations throughout the progression of CC. Methods: Lewis Lung Carcinoma cells (LLC) or
Phosphate Buffered Saline (PBS, control) were injected into the hind-flank of wildtype
C57BL6/J mice at 8 wks of age, and tumor allowed to develop for 1, 2, 3, or 4 wks before
euthanasia. RNA was isolated from the gastrocnemius and RNA sequencing performed. Results:
RNA sequencing showed widespread alterations in LLC when compared to PBS animals with
largest differences seen in 4 wk LLC compared to other conditions. Commonly altered pathways
included: Oxidative Phosphorylation, Mitochondrial Dysfunction, and Protein Ubiquitination.
Discussion: We demonstrated that alterations in the muscle belly likely occur in phases
beginning with early mitochondrial degenerations, which now appear to lead to large
transcriptomic shifts concurrent to the onset of muscle atrophy. In agreement with previous
work, we observed multiple aspects related to degeneration of mitochondria and oxidative
metabolism. The early onset of these alterations shows a need for early interventions in order to
effectively ameliorate the effects of CC.
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Cancer-Cachexia Overview
Approximately 39.6% of men and women will receive a cancer diagnosis during their
lifetime, with an estimated 1,685,210 new cancer diagnoses in the United States in 2016 alone,
of which 595,690 will eventually die as a result of their cancer diagnosis (1). On a global scale, it
is anticipated that annual new cancer diagnoses will surpass 20 million as soon as 2025 (2). In a
2011 statement from the World Health Organization, cancer is now recognized as one of the
leading causes of death within the Western World, recently surpassing coronary heart disease
and all stroke-related mortality (2). Since 1970 mortality rates for other common life threatening
diseases have declined significantly (3). The most significant of which were heart disease and
cerebrovascular disease, with a 62% and 73% decline in mortality respectively (3). In this same
timeline, mortality rates due to cancer have only declined 12% (3). This shows us that there is a
need for new evidences to enhance the treatment of cancer. One of the biggest issues facing the
treatment of cancer is the vast number of types and causes of cancer as well as the difficulty in
treating such a multi-faceted disease.
One significant aspect of these cancer diagnoses is that up to 80% of individuals will
experience varying degrees of Cancer-Cachexia (CC) (4). CC is defined as the ongoing loss of
muscle mass, which may be accompanied by wasting of other tissues, that cannot be fully
reversed by nutritional interventions alone (5, 6). CC is estimated to be responsible for 20-40%
of cancer-related deaths, depending on the type and severity of cancer present, along with how
soon preventative measures are taken (7). Currently, the exact mechanisms responsible for the
development of CC are not well understood, but it is clear that CC is a serious health care
concern that lacks adequate interventions.
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CC is a multifaceted, complex phenomenon. By definition nutritional changes alone cannot
reverse the effects of CC, which in turn suggests that the muscle wasting is largely due to altered
metabolism both systemically and intramuscularly (7). In order for any form of skeletal muscle
atrophy to occur the rate of protein degradation must surpass the rate of protein synthesis,
leading to a net loss in total muscle protein. This effect has been seen and exhaustively analyzed
in other cases of atrophy, notably: denervation (8), sarcopenia (9), and morbid obesity (10). In
the case of CC, however, the specific metabolic dysfunctions are not fully understood. Most
current investigations of CC primarily focus on comparisons between the pre- and postcachectic state, and offer little insight into the development of the condition. When facing a
disease with such a high mortality rate, it is essential to understand how to effectively prevent
CC from developing in the first place. This review of literature will outline known mechanisms
in CC and the likely utility of –omics based approaches to further understand the development of
CC.
Known Pathways of Muscular Atrophy in Cancer-Cachexia
An in-depth understanding of CC is essential for understanding the progression of this
disease and any potential interventions to truly reverse or reduce progression. In order to impact
CC before there is significant muscle wasting, we must develop an understanding of altered
cellular mechanisms at early stages in this complex disease. There are numerous mechanisms
and alterations that contribute to dysregulation of muscle protein turnover in CC (11, 12). These
include, but are not limited to, protein synthetic, myogenic, autophagic, proteasomal,
inflammatory, and mitochondrial pathways (11-14). The following section will analyze current
research in these areas.
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Protein Synthetic Pathways
In CC, rates of protein synthesis are initially decreased ~19% and progress toward ~50%
when compared to healthy controls throughout the progression of CC (15). Some factors that
influence signal transduction pathways regulating protein synthesis are mechanical stimuli,
anabolic and catabolic hormones, and energy balance (16). The regulation of protein synthesis is
largely accomplished via mTOR-related signal transduction pathways (16). By far the most
predominant signaling regulator of translation initiation is the AKT/mTOR pathway, of which
insulin and IGF-1 are major activators (17). In CC, protein synthesis is down regulated in a
number of ways. Both serum IGF-1 and the synthesis of IGF-1 from skeletal muscle are impaired
in CC (18). Also, a decrease in mTOR activation is noticeable in early and late stage CC in mice
following MAC16 tumor implantation (19). Though many theories related to decreased mTOR
activation have been proposed, the two most promising appear to work through AMPK and
systemic inflammation (20). AMPK inhibits mTOR by preventing the interaction with both
p70S6K and 4E-BP1 (21). Inflammatory proteins, such as IL-6, also reduce the activation of
mTOR directly and indirectly through phosphorylation of AMPK, among other impacts of IL-6
and inflammatory cytokines (20). Both of these potential mechanisms of protein synthesis
reduction via the mTOR pathway have been observed in models of CC (19, 22).
Myogenic Pathways
In CC, there is significant damage to the sarcolemma. This becomes problematic
whenever combined with decreased capacity for myogenesis, which has been linked to
dysregulated myogenesis and muscle loss (23). It has been suggested that this is due to an
increase in compensatory protein synthesis via other pathways, which are not present in CC (24).
Satellite cell function is likely reduced through the NF-κB pathway (25). NF-κB activation leads
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to sustained Pax7 activation, which in turn likely propagates a self-renewal signal in myogenic
cells, rendering them unable to progress through differentiation (25). Despite these findings,
Satellite Cell depletion alone does not appear to induce muscle atrophy but at the least may in
part explain inabilities to reverse cachexia (24). Furthermore, NF-κB mediated Pax7 activation
has also been shown to inhibit MyoD synthesis (25) Myogenic regulatory factors MyoD,
Myogenin, Myf5, and Myf6 demonstrate some interplay with IGF-1 (26). Since reduced IGF-1
signaling has been observed in CC (18), it is likely impairment of these processes is interrelated.
Another potential area of myogenesis dysregulation has been examined in denervation models; it
has been shown that denervation results in an increase in Myogenin production, which seems to
lead to the activation of E3 ubiquitin ligases MuRF1 and Atrogin which would ultimately
promote protein degradation (8).
Protein Degradation
Autophagy is often described as a process that is inversely related to protein synthesis
(27). It has been shown that autophagy is dysregulated in CC (13). Autophagy is a process of
lysosomal degradation whereby aggregated protein and damaged organelles are engulfed by an
autophagosome prior to ultimate joining with lysosome and degradation. Increased autophagy in
CC is evidenced by an increased LC3 II content, which implies increased autophagasome
activity (13). Lysosomal clearance may also be negatively impacted, as evidenced by increased
p62 levels (13). Another likely method for increased muscle loss is the combination of mTOR
inhibition and enhanced AMPK phosphorylation, which increases autophagy signaling via
increased Beclin activation (28-30). Though it has not been adequately examined, there is
potential for increased Reactive Oxygen Species (ROS) production in skeletal muscle, which
may promote autophagy (28, 29). While there are signs of impaired autophagy in CC, the
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inconsistent nature of these findings leads us to conclude that there are likely more significant
mechanisms of muscular atrophy at play, such as proteolysis.
Proteasome-induced muscular atrophy has been observed in CC (31). The proteasome is
essential for cellular function, as demonstrated by extreme oxidative stress and cell death
following the administration of proteasome inhibitors (32). Though the proteasome is essential
for cellular health, over-activation of this pathway leads to muscular atrophy as evidenced in
high-fat diet in mice (33). This over-activation of proteolysis has been observed in CC and is
highly implicated as a primary pathway of protein degradation through which muscle wasting
occurs in this disease, despite adequate mechanistic understanding (34). Due to the complex
nature of proteolysis and the negative implications of proteasome inhibitors on cellular health, it
is imperative that future literature investigates the signaling pathways that cause the observed
over-activation of proteolysis in CC.
In skeletal muscle there are two major muscle specific E3 ligases that are particularly
involved in the induction of skeletal muscle wasting: Atrogin-1 and MuRF-1 (35). Under normal
conditions, Atrogin-1 and MuRF-1 are scarcely expressed (36). Atrogin-1 and MuRF-1 facilitate
the ubiquitination of many proteins involved in hypertrophic signaling, including proteins
involved in: ATP generation, protein synthesis, myogenic regulatory factors, and myofibrillar
proteins (36). Both Atrogin-1 and MuRF-1 are regulated by the transcription factors FOX-O 1
and FOX-O 3 in skeletal muscle (37). FOX-O 1/3 signaling appears to modify protein synthetic
signaling by via negative regulation of AKT phosphorylation (38). In addition to modifying
protein synthesis, FOX-O 1/3 signaling also upregulates autophagic processes (39). FOX-O 1/3
signaling seems to be promoted by cellular stresses, which supports theories that FOX-O 1/3
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signaling is modulated in CC (39). Clearly, there is a dysregulation in muscle protein balance in
CC; however, the instigating signals leading to this imbalance are not well understood.
Inflammatory Pathways
CC is a systemic disease that affects the muscle, fat, brain, liver, heart, blood, spleen, and
likely numerous other tissues (40). This systemic response is largely due to circulating
inflammatory cytokines that create a proinflammatory environment, which has been
demonstrated in models of CC (41). Specific inflammatory cytokines that have been linked to the
progression of CC are TNF-α, STAT3, C-Reactive Proteins, MCP-1, IL-6, and IL-1 beta (42-44).
In this review of literature we will focus on the roles of IL-6 and TNF-α, as they are the most
thoroughly investigated inflammatory factors known to be modified in CC.
IL-6 is one of the most heavily examined inflammatory cytokines in CC literature to date.
Exogenous IL-6 and related cytokines alone can induce most symptoms of CC, including muscle
and fat wasting, whereas conversely the inhibition of IL-6 reduces muscle loss in CC (45).
Following tumor growth in ApcMin/+ mice dramatically increased plasma IL-6 levels (46). Mice
lacking gp130, the cellular cytokine receptor for IL-6, and therefore unreceptive to IL-6 exhibit
diminished symptoms of CC as well as pathological phosphorylation of p38, MAPK, STAT3,
and FOXO3 (45). Chronic phosphorylation of p38α/β MAPK can lead to impairments in the
ability of skeletal muscle to regenerate (47). IL-6 (via the IL-6->JAK->STAT3 pathway) is
causally linked to many of the effects of CC, notable skeletal muscle atrophy, cardiac
dysfunction, and hypothalamic inflammation (20, 30, 40). Furthermore, chronic IL-6 exposure
decreases protein synthesis via inhibition of mTOR and induction of proteolysis (20, 48).
Combined these series of evidences strongly indicate a significant role for IL-6 in mediating
muscle wasting phenotypes such as in CC.
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TNF-α is an inflammatory cytokine present in the tumor microenvironment that has been
connected with carcinogenesis, specifically in production of reactive oxygen and nitrogen
species, and is involved with mechanisms responsible for epithelial mesenchymal transition,
angiogenesis, and metastasis (49). TNF-α has also been implicated in the reduction of protein,
lipid, and glycogen synthesis (50). TNF-α is further a promoter of apoptopic signaling in Type II
muscle fibers, which alone can induce muscle atrophy (51). TNF-α expression can also be
responsible for increased production of ubiquitin and other key E3 ubiquitin ligases, notably
Atrogin and MuRF-1 (52). This can lead to a buildup of ubiquitinated proteins which promote
protein degradation and shift net protein balance toward a loss, leading to reduced muscle protein
and wasting (53). The role of this mechanism in CC is further supported by work from Zhang et
al., who implanted mice with tumor and treated them with MG132, a proteasome inhibitor that
specifically reduces the breakdown of ubiquitin-conjugated proteins (54). Treatment with
MG132 significantly alleviated CC related muscle atrophy (54). It appears increased TNF-α
levels significantly contribute to the muscle wasting seen in CC by increasing protein
degradation, decreasing protein synthesis, and negatively impacting energy balance.
Mitochondrial Modulation
Mitochondrial function is another recently examined aspect of CC, which demonstrates a
fiber-type specific effect: specifically that glycolytic muscle fibers are much more susceptible to
wasting (55). It has been demonstrated that mitochondrial dysfunction can cause muscle wasting,
via pathways that are observed in CC (55). One possible explanation for this relationship may be
reduced ATP output from dysfunctional mitochondria. If there is insufficient ATP for protein
synthesis, then rates of protein synthesis may decrease as rates of protein degradation increase as
the cell attempts to produce ATP via alternative pathways. Secondly, increased ROS production
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from dysfunctional mitochondria has been causally implicated in inducing atrophy (56). FOXO3
is activated by the presence ROS, and increases autophagy in order to reduce ROS production
(57). Interestingly, work by White et al. has demonstrated reductions in muscle oxidative
phenotype and mitochondrial content concomitant with dysregulated mitochondrial dynamics in
CC (15). These findings may suggest a prominent role for mitochondria in the development of
this condition.
Current Pharmacological Interventions in Cancer-Cachexia
The current definition of CC states that it is primarily a muscle atrophy that cannot be
reversed by nutritional interventions alone (5). However, most current pharmaceutical
interventions focus on increasing the appetite of patients, increasing the protein-synthetic impact
of the foods ingested, or pharmacologically increasing anabolic hormone signaling within the
(12). It is of the utmost importance to understand the methodology as well as the successes or
failures of interventions focused on addressing hypophagia, or decreased energy intake and
eating behavior, in order to understand the need and direction for future research into the
mechanistic aspects of CC.
The most common treatment methods of CC are focused on increasing appetite.
Megestrol Acetate administration has demonstrated improvements in appetite, fatigue, and
general well being (58). With Megestrol Acetate, there is a dose-dependent increase in appetite
within one week and weight gain that begins after several weeks; however this effect is seen in
less than 25% of patients suffering from CC (58). Another medical intervention aimed at
increasing appetite is Medroxyprogesterone Acetate. Medroxyprogesterone Acetate use in
patients with severe CC has been shown to be effective at increasing appetite within 6 weeks as
well as lead to significant increases in total body mass (+0.6 kg +/- 4.4 kg) when compared to the
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placebo group, who lost weight throughout the course of this experiment (-1.4 kg +/- 4.6 kg)
(59). Another medication being used in the treatment of CC is Dronabinol, a synthetic
cannabinoid. Despite successes in treating wasting associated with Human Immunodeficiency
Virus/Acquired Immunodeficiency Syndrome, it appears to have limited efficacy with CC (60).
Another cannabinoid, Thalidomide, is showing some promise in the treatment of CC. A recent
randomized, placebo controlled trial showed that Thalidomide treatment attenuated lean body
mass loss in patients with advanced CC despite no difference in appetite between treatment and
control groups (61). While treatments aimed at increasing energy intake by increasing appetite
have shown some promise, the results are highly variable and have limited success rates. By the
very definition of CC, these interventions focused on increasing nutritional intake would appear
to be unlikely to exhibit high efficacy in the reversal of muscular atrophy.
Utilization of testosterone derivatives to increase lean mass has also been examined.
Nandrolone Propionate administration to MCG 101 sarcoma bearing mice (C57BL/6J) showed
an increase in body weight, but this was attributed mostly to fluid retention with little to no
increase in muscle wet weight (62). One of the most promising therapeutic treatments so far has
been combination treatment with Oxandrolone, another Testosterone derivative, and Megestrol
Acetate. Treatment with Oxandrolone alone showed significant increases in lean body mass and
a decrease in fat mass (63). These improvements have shown potential as a pharmaceutical
intervention to offset the effects of CC. These interventions have shown some promise in treating
CC, but still do not address the underlying mechanistic causes. In order to make a significant
impact on CC mortality rates, a better understanding of its causes and mechanisms is required in
order to stop the disease before it causes significant muscle wasting.
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Another direction of research has been through inhibition of IL-6. In AMin/+ mice,
administration of PDTC (an anti-inflammatory and antioxidant that inhibits STAT3 and NF-kB
signaling in mice) effectively attenuated the muscle loss in CC (55) A review of six clinical trials
administering various monoclonal IL-6 antibodies has shown that there is a significant reduction
in cancer-related symptoms including CC, fever, and pain in humans (64). These investigations
into the inhibition of inflammatory cytokines show an increased need to understand the
underlying cell-processes that contribute to CC. However, the overall lack of efficacy in
treatments for CC emphasizes the need to reconsider our approach to treatment.
Summary of Known Mechanisms and Treatments for Cancer-Cachexia
When examining the mechanisms of CC, we are limited due to most studies taking place
in the post-cachectic state. Nonetheless, this research offers valuable insight into modulated
pathways that affect those suffering from CC. We have been able to see, through various models
and methodologies, that there is a significant reduction in protein synthesis via inhibition of the
AKT/mTOR pathway. Protein degradation is significantly increased in CC, both through
ubiquitination and proteolysis. We have also examined that there is significant reduction in
myogenic capacity within muscle, largely as a result of the NF-kB pathway. The common thread
of Atrogin-1 and MuRF-1 increasing degradation, combined with increased Myogenin levels and
altered myogenesis imply that the findings of Olsen et al. may also be present in models of CC
(8). The chronic increase in inflammatory cytokines IL-6 and TNF-a are implicated to contribute
to dysregulation in protein synthesis, myogenesis, and protein degradation in models of CC.
The current lack of efficacious treatments for CC now requires the utilization of new
approaches to the study and identification of underlying mechanisms. Specifically, recent
literature calls for a treatment focus on prevention, rather than reversal, of CC (65). Of note,

10

however, is a relative dearth of data examining the progression of CC. To best develop
preventive measures it becomes critical to understand the process of cachectic development
rather than a sole focus on the intracellular modulation in the cachectic state itself. Some prior
work has inferred progression of this condition by examining varying degrees of cachexia in
spontaneous colorectal cancer, but to our knowledge no prior efforts have been put forward to
examine the direct time course of progression of CC.
To this end, Fearon et al. has recently called for the use of –omics approaches in order to
examine intracellular alterations in this disease (66). These approaches allow for assessments to
consider the complex and multifaceted nature of CC to best determine affected processes that
may promote this muscle wasting. As Fearon et al. have stated, the end result is more than the
sum of its parts (66). Consideration of –omics approaches and early stage developments may
hold the key to identify novel mechanisms and pathway interactions key to the development of
new and efficacious therapies.
Purpose
Therefore, the purpose of this thesis will be to examine the progression of CC over time
course utilizing transcriptomic methodologies to identify significantly modulated pathways. By
doing so I will fill major knowledge gaps in by examining both the timecourse progression and
utilizing RNA sequencing methods to identify novel altered transcripts and affected pathways
across the development of CC.
Objectives for Data Analysis
In order to further elucidate the mechanisms behind CC, this investigation will: 1)
describe phenotypic development of CC, including body weight, tissue weight, and tumor weight
2) determine the number of significant differentially expressed genes in the progression of CC in
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the gastrocnemius muscle 3) determine the number and indentity of significant genes during
early stage CC prior to development of the cachectic condition 4) determine the top canonical
pathways impacted by identified differentially expressed genes in comparison of control and
cachectic groups.
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Materials and Methods
Animals and Interventions
All methods were be approved by the Institutional Animal Care and Use Committee of
the University of Arkansas. A cohort of C57BL6/J mice (Jackson Laboratories, Bar Harbor, ME)
from a larger study (Brown et al.; manuscript in review) was randomly selected, and phenotypic
statistics were assessed to ensure representation of the larger cohort. Mice were housed in a
temperature-controlled room on a 12:12h light-dark cycle with food and water provided ad
libitum. Lewis Lung Carcinoma (LLC) cells were injected subcutaneously into the hind flank of
C57BL6/J mice at 1 x 106 cells in 100 µL PBS as previously described (45, 67). Control mice
received a similar injection of 100µL PBS. To examine progression of CC over time course,
tumors were allowed to grow for 1, 2, 3, or 4 weeks; mice injected with PBS were euthanized at
12 weeks of age in order to age match Week 4 LLC mice. At the appropriate time point above
mice were anesthetized under isoflurane anesthesia, and gastrocnemius muscles were removed
and snap-frozen before storage at -80°C prior to euthanization. To control for alterations in total
body size between groups, tibia lengths were assessed as a surrogate of body size independent of
total body weight. No differences were observed in tibia length among groups, therefore
descriptive data are presented as raw wet weights.
RNA Isolation and Quality
RNA isolation was performed as previously described (68). Whole gastrocnemius muscle
form each animal was pulverized at the temperature of liquid nitrogen allowing a uniform
mixture of the full muscle to be represented in all experiments. Approximately 120 mg of
pulverized muscle was then suspended in 1 mL of Trizol (Invitrogen cat # 10296-028). Samples
were then homogenized using Polytron for approximately 5 seconds before being transferred into
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1.5 mL cryotube and placed on ice. After 15 minutes, samples were placed in centrifuge for 10
minutes and the clear supernatant placed into a new tube. 200 µl of 100% chloroform was then
added, and the sample centrifuged for 25 minutes. The clear solution was removed from the top
and placed in a new, sterile tube. An equal amount to the sample of 70% DEPC EtOH was
added, and the sample loaded in to an RNeasy column. RNA isolation was then performed using
an Ambion RNA Isolation Kit (Life Technologies, Carlsbad, CA). RNA quality and
concentration were determined using Agilent 2200 TapeStation (Agilent Technologies, Santa
Clara, CA, USA). Mean RINe scores from TapeStation analysis for submitted samples were 8.56
± 0.06 (mean ± SEM).
RNA Sequencing and Data Analysis
RNA sequencing was completed at the Genomics Core at Michigan State University
(East Lansing, MI). Libraries were prepared using the Illumina TruSeq Stranded mRNA Library
Preparation Kit. The pool was loaded onto Illumina HiSeq 2500 High Output flow cell (v4) and
sequenced in a 1x50bp single read format using HiSeq v4 SBS reagents. Base calling was done
by Illumina Real Time Analysis (RTA) v1.18.64 and output of RTA was demultiplexed and
converted to FastQ format with Illumina Bcl2fastq v1.8.4. Quality control of raw reads was
determined using FastQC tool kit (Babraham Bioinformatics, http://bioinformatics.babraham.
ac.uk/projects/fastqc) The reads were then aligned with reference genome of Mus
musculus (GRCm38.p5) downloaded from NCBI using Hisat2 tool (69) and reads aligning to
gene exons were counted using HTSeq framework (70). List of differentially expressed (DE)
genes between individual experimental groups was obtained by analyzing HTSeq counts using
DESeq2 package by applying regularized log transformation (71). DE genes were identified as
surpassing threshold levels of FDR = 0.05 and Log2FC = 0.6. Ingenuity Pathway Analysis (IPA;
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Qiagen, Valencia, CA; http://www.ingenuity.com) software was used for canonical pathway
analysis and functional annotation. Prediction of upstream transcription factor signatures for DE
genes was performed using Dire tool (dire.dcode.org). Visualization of intersections of genes
between experimental groups was performed using UpSetR package (72) and subsequent
functional clustering of individual sets was based on Gene Ontology and performed using
AmiGO tool (73). Two separate investigators analyzed RNA Sequencing data (I.C. and B.K.)
with strong agreement between analyses.
Comparison of RNA Sequencing to the MitoCarta
Identified DE genes were compared to the mouse MitoCarta 2.0 utilizing custom
computer software. Identified genes that were identified by RNA Sequencing as DE and
appeared in the MitoCarta 2.0 were tallied (74).
Statistical Analysis
A One-Way ANOVA was employed for the global analysis for all variables of interest.
Descriptive data including body, tumor and tissue weights were analyzed using SAS version 9.4
(SAS, Cary, NC, USA). Data from RNA sequencing analysis was analyzed using JMP
Genomics. The comparison-wise error rate, α, was set at 0.05 for all statistical tests. For
descriptive data, when significant F-ratios were found, multiple comparisons were made among
all groups using Student-Newman-Keuls post hoc analysis. For sequencing analysis, when
significant F-ratios were found, multiple comparisons were made among all groups with p-value
correction through FDR calculation. DE genes were identified as surpassing threshold levels of
FDR = 0.05 and Log2FC = 0.6.
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Results
Phenotypic description of LLC-induced muscle atrophy across time course
These analyses were performed on a cohort of animals from a larger study (Brown et al.;
manuscript in review) representing 8 mice per condition. For the current cohort, body weights
without tumor were not different between experimental conditions across the 4 weeks cancer
development despite significantly lower (~10-18%) muscle weights of the Gastrocenmius,
Tibialis Anterior, Extensor Digitorum Longus, and Plantaris in Week 4 LLC animals (Table 1).
Epididymal fat mass also was significantly lower (~33%) in Week 3 and Week 4 LLC animals
compared to PBS animals (Table 1). Spleen mass was ~300% greater in Week 3 LLC, and
further enlarged ~500% in Week 4 LLC compared to PBS animals (Table 1).

RNA Sequencing effectively discriminates cachectic vs. non-cachectic animals
Approximately 25,000 total genes were identified in RNA Sequencing. Two separate
laboratory groups performed RNA sequencing analysis with a high level of agreement (data not
shown). Following FDR correction most statistically significant comparison-to-comparison
differences are seen when examining Week 4 LLC mice compared to all other groups (Figure
1A). Heirarchical clustering, PCA analysis and sample-to-sample distances demonstrate good
discrimination between experimental conditions (Figure 1B-D). Heatmap of hierarchical
clustering of the top 1,000 most highly expressed genes showed grouping of Week 4 LLC mice
with significant differences in gene expressions compared to animals from all other experimental
conditions (Figure 1B).
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Differentially expressed genes appeared primarily in comparisons to Week 4 LLC mice
Volcano plots of DE genes in each individual comparison are shown in Figure 2. These
plots show that the highest alterations in gene expression are seen when comparing Week 4 LLC
animals to other groups. The number of DE genes was tallied and revealed 932 down-regulated
and 993 up-regulated genes in 4 wk LLC compared to PBS control (Table 2).

Pathway analysis of differentially expressed genes for all comparisons
IPA pathway analysis was performed for all comparisons with sufficient number of DE
genes (Figure 3). Commonly impacted pathways across individual comparison groups in
descending order of frequency included granulocyte adhesion and diapedesis, protein
ubiquitination, TH1 and TH2 activation, Fcy-receptor mediated phagocytosis in macrophages
and monocytes, leukocyte extravasation, aryl-hydrocarbon receptor signaling, PPARα and RXRα
activation, TH2 pathway, agranulocyte adhesion and diapedesis, oxidative phosphorylation,
mitochondrial dysfunction, TCA Cycle II (Eukaryotic), LXR/RXR activation, and B cell receptor
signaling (Figure 3). Venn diagram for commonalities among multiple comparisons elucidates a
clear relationship between Week 4 LLC animals and altered gene expression (Figure 4). When
comparing Week 4 LLC to PBS, Week 1 LLC, and Week 2 LLC, we observe alterations in ATP
synthesis coupled electron transport, oxidative phosphorylation, regulation of tumor necrosis
factor production, ubiquitin-dependent protein catabolic processes, and cellular protein catabolic
processes (Figure 4). Considering the common occurrence of processes including mitochondrial
dysfunction and electron transport along with our prior finding (Brown et al.; manuscript in
review), we performed IPA analysis of mitochondrial dysfunction between Week 4 LLC and
PBS control groups showing 93 of 171 known genes in mitochondrial dysfunction affected
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(Figure 5). Furthermore, DE genes in each comparison were matched against the MitoCarta 2.0
(Table 3). Most notably we observed: 255 DE genes in the comparison of Week 4 LLC to Week
2 LLC , 213 DE genes in the Week 4 LLC to Week 1 LLC comparison, and 340 similar genes in
the Week 4 LLC to PBS comparison with matches to the MitoCarta.

Analysis of transcription factors common to DE genes among comparisons
Subsequently we analyzed DE genes in each comparison for transcription factors likely
mediating the alterations observed. Transcription factors and families of transcription factors that
appeared among multiple comparisons included: OCT1, SRY, Myogenin, DR3, ZIC2, TBX5,
SREBP1, STAT, PU1, T3R, TAL1BETAITF2, HSF, LEF1, S8, ETS, and SOX9_BP1.
Furthermore, multiple transcriptional factors with specific influence over muscle processes (i.e.,
myogenesis) were observed including: Myogenin, FOXO3, NF-kB p65, and PAX (Figure 6).
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Discussion
We are the first to combine RNA sequencing techniques with a time-course design to
gain insight into the transcriptomic alterations in the development of muscle wasting in CC. We
recently demonstrated early onset mitochondrial derangements well prior to development of
muscle wasting in CC (Brown et al.; manuscript in review), this investigation has furthered that
work by clearly demonstrated potential pathways involved in the pathology of CC induced
muscle atrophy. The utilization of the time course design in conjunction with RNA sequencing
allowed us to explore transciptomic shifts through the development of CC in tumor-bearing
animals. Our analyses demonstrated clear differentiation between experimental groups. This
effect can be clearly seen in Figure 2 as the number of DE genes massively increases, both
positively and negatively, when comparing Week 4 LLC animals to all other groups suggesting a
clear point at which large scale transcriptomic shifts occur in conjunction with the onset of
muscle wasting. We can also see distinct modulation in critical pathways, namely autoimmune
function, protein ubiquitination, and oxidative metabolism, as muscle wasting develops. In
conjunction with our prior report, we now see that mitochondrial impacts appear central to
development of muscle wasting in CC, and that CC develops in a clear progression from early
onset metabolic derangements to large transcriptomic shifts at the onset of wasting itself. This
study will help to create a basis for future research by identifying future pathways for analysis.
Our experimental model was successful as per the utilized definition of CC: the ongoing
loss of muscle mass, which may be accompanied by wasting of other tissues, which cannot be
fully reversed by nutritional interventions alone (5). Our assays were able to effectively
differentiate between pre- and post- cachectic conditions, seen in Figure 1. Phenotypic analysis
of muscle wet-weights showed significant decrease in muscle mass and increases in spleen
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weights beginning in Week 3 LLC animals, consistent with previously reports using LLC
implantation models of CC (75, 76). Upon examination of Figure 2, a clear increase in DE genes
is seen when comparing Week 4 LLC animals to other groups (both LLC and PBS groups).
Phenotypic analysis of Week 4 LLC animals shows ~10-18% reduction in muscle wet weights
along with a ~500% enlargement of the spleen. Hierarchical clustering analysis (Figure 1B)
showed grouping of Week 4 LLC animals when compared to PBS controls and other
developmental stages of LLC implanted mice.
When examining the shift in transcriptomic signaling, large shifts do not occur until
stages where significant muscle wasting is evident (Figure 2 and Table 2). In contrast, we have
recently observed impairment in functional mitochondrial health preceding decreases in muscle
wet weight (Brown et al.; manuscript in review) which were observed as early as 1 week
following tumor implantation through a doubling in mitochondrial ROS emission. It is then of
significant interest that large transcriptomic shifts do not occur until 4 weeks following tumor
implantation. Thus the data presented here, combined with our early findings, suggest that
alterations within the muscle belly occur first through functional changes in metabolic
parameters and ultimately leads to large transcriptomic shifts concurrent to measurable muscle
wasting. These combined findings suggest that intramuscular alterations occur via a pair of
trigger points: one early leading to functional metabolic derangements and a second wherein
muscle wasting and transcriptomic shifts occur.
Prior literature has tied CC to alterations in muscle protein degradation, protein synthesis
and inflammatory signaling, among others (11-14). Here we have built upon this by performing
IPA analysis of transcriptomic data across development of CC to provide a more clear
understanding of the totality of cellular processes impacted in this condition. Consistent with that
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prior work we have identified alterations in inflammatory, immune, protein ubiquitination, and
protein synthetic pathways. We further identified altered pathways throughout development of
the condition seeing alterations in such pathways as circadian rhythm signaling, among others.
When examining the pathways that are specifically modulated in post-cachectic groups when
compared to pre-cachectic groups and PBS controls we see negative regulation of several
important

pathways,

namely:

actin

filament

depolymerization,

cell

morphogenesis,

supramolecular fiber organization, cytoskeleton organization, and cell adhesion. These combined
pathways suggest that tumor-bearing animals display impaired capabilities to maintain cellular
morphology and structure, which will ultimately lead to impaired motor function. We also see a
large increase in pathways associated with DNA maintenance, transcription, and translation,
namely; histone acetylation, chromatin assembly and disassembly, translation, RNA splicing,
DNA repair, and intracellular protein transport. Thus the cells ability to encode and provide
functional protein becomes diminished. Therefore, in conjunction with some classic pathways
altered in the wasting condition of CC, we see alterations in many additional pathways, which
are critical for maintenance of total cellular health. The alteration of these pathways, combined
with the large increase in DE genes, imply that in Week 4 LLC animals the tumor is beginning to
breakdown essential functions within the animal.
Considering our prior work demonstrating functional mitochondrial degeneration early in
development of CC, it is most interesting that many pathways involved in oxidative metabolism
were identified. Such identified pathways included: ATP synthesis coupled electron transport,
oxidative phosphorylation, mitochondrial dysfunction, and mitochondrial organization. In
addition to these specific aspects of mitochondrial energy metabolism we note impacts in
signaling through AMPK and PPARα, suggesting that both direct functional components as well

21

as mitochondrial regulatory pathways are impacted. That so many of the affected pathways
identified are vital either to direct mitochondrial quality or to the regulation therein is consistent
with our recent findings of early onset functional mitochondrial degenerations in these animals.
These combined findings are strongly indicative of a critical role for mitochondrial maintenance
in development of muscular atrophy in CC. This would lead to a decreased capacity for ATP
production, which could create chronic low-energy conditions within the muscle. This effect can
be seen in increased AMPK signaling when comparing Week 4 LLC to PBS groups in Figure 3.
Models of CC also demonstrate a decrease in oxidative capacity and an increase in mitochondrial
ROS production (Brown et al.; manuscript in review). We also noted increases in NO and ROS
in macrophages when comparing Week 4 LLC to Week 1 LLC animals, consistent with findings
by Brown et al (manuscript in review).
Next, to provide insight to the means by which identified DE genes were altered in
progression of CC, we performed transcription factor analyses to identify likely regulations of
these genes. Interestingly, we identified transcription factors commonly associated with
processes such as myogenesis, tumor necrotic factors, sterol biosynthesis, immunosuppression,
and increased angiogenesis (Figure 6). The alterations in these potential transcription factors,
combined with the large quantity of DE genes over the course of CC progression, further support
that the tumor is systemically breaking down essential functions within the animal.

Summary
Our experiment was able to effectively demonstrate large-scale transcriptomic alterations
throughout the timecourse of CC progression. The largest difference in expression was observed
when comparing Week 4 LLC animals, which demonstrated the cachectic phenotype, compared
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to all other conditions. Combined with our prior work (Brown et al.; manuscript in review) we
now see that alterations in the muscle belly likely occur in phases beginning with early
mitochondrial degenerations, which now appear to lead to large transcriptomic shifts concurrent
to the onset of muscle atrophy. We were then able to identify multiple pathways, both in classic
protein turnover and inflammatory pathways. We also identified multiple other cell functions
contributing to the development of the cachectic phenotype, which included aspects of
maintenance of cell structure and DNA repair/transcription. Furthermore, in agreement with our
prior work (Brown et al.; manuscript in review), we observed multiple aspects related to
degeneration of mitochondria and oxidative metabolism. The data presented herein has provided
novel evidence for altered genes and pathways throughout the progression of CC in tumor
bearing mice. Future studies should utilize these data to identify which pathways may be critical
to allowing the development of muscle atrophy in CC.

Objectives for Data Analysis
Relative to my experimental objectives, the cachectic phenotype presented at 4 weeks
following tumor implantation, as seen in Table 1 (Objective 1). We observed that 5,538 of genes
were DE in tumor-implanted mice when compared to PBS controls, as seen in Table 2 (Objective
2). We further observed that, of the 5,538 DE genes, 140 genes were DE prior to the
development of the cachectic phenotype, as seen in Figures 2 and 3 (Objective 3). When
comparing PBS controls to Week 4 LLC animals, the top identified canonical pathways (As seen
in

Figure

3)

were:

Oxidative

Phosphorylation,

Mitochondrial

Dysfunction,

Protein

Ubiquitination, and TCA Cycle II (Objective 4).
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Figures and Tables
Legends:
Table 1: Phenotypic Data of Cohort. All values are represented as “mean ± SEM”. * signifies
significant difference (p ≤ 0.05) from PBS. # signifies significant difference (p ≤ 0.05) from 1
wk.
Figure 1: A) Summary table of the number of up and down regulated genes in individual group
comparisons. Red signifies down-regulated genes; green signifies up-regulated genes. B)
Hierarchical Clustering Heatmap of 1000 most expressed genes. Red signifies increased gene
expression, while blue signifies decreased gene expression. C) Principle Component Analysis
(PCA) analysis of individual samples. D) Heatmap of sample-to-sample distances. Darker colors
indicate greater differences in expression.
Figure 2: Volcano plots of differentially expressed genes in individual comparisons. Blue
signifies a gene that reached an FDR< 0.05, but log2(Fold Change) was not >|0.6|. Red signifies a
gene that reached a FDR < 0.05 and log2(Fold Change) > |0.6|.
Table 2: Summary table of the number of up and down regulated genes in individual group
comparisons that were differentially expressed (FDR<0.05, log2(Fold Change) > |0.6|). Red
signifies down-regulated DE genes; green signifies up-regulated DE genes.
Figure 3: IPA analysis of comparisons with sufficient number of DE genes. Graphs identify 10
most highly affected pathways with the highest significance. If applicable, z-score indicates
whether pathway was up- or down- regulated.
Supplemental Figure 1: IPA analysis of comparisons with sufficient number of DE genes.
Graphs demonstrate significantly altered biological processes and diseases that show similar
modulation.
Figure 4: Venn diagram of the number of genes that were common or exclusive between
comparison groups. Illustrations below show gene ontology clustering of subsets that contain
sufficient amount of differentially expressed genes.
Figure 5: DE genes in Mitochondrial Dysfunction. All colored in genes were DE when
comparing Week 4 LLC to PBS controls.
Table 3: Portion of genes with a positive match on the MitoCarta 2.0
Figure 6: IPA analysis of comparisons with sufficient number of DE genes. Illustrations show
prediction of common regulatory elements for transcription factors in identified up- and downregulated genes (dire.dcode.org).
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Table 1:
PBS

1 wk

2 wk

3 wk

4 wk

Body Weight
(with Tumor) (g)

n/a

23.3 ± .4

23.1 ± .6

23.2 ± 1.0

26.6 ± 0.6 #

Tumor Weight (g)

n/a

0.03 ± 0.01

0.14 ± 0.04

0.66 ± 0.15

3.56 ± 0.45 #

Body Weight
(without Tumor) (g)

24.3 ± 0.5

23.2 ± 0.4

23.0 ± 0.6

22.5 ± 0.8

23.1 ± 0.3

Gastrocnemius (mg)

134.0 ± 3.7

122.6 ± 3.1

125.7 ± 4.3

119.3 ± 3.5

111.6 ± 3.6 *#

Tibialis Anterior (mg)

45.2 ± 1.6

41.2 ± 1.3

43.2 ± 1.3

40.6 ± 1.8 *

36.0 ± .9 *#

EDL (mg)

9.1 ± 0.6

9.5 ± 0.3

9.9 ± 0.4

9.6 ± 0.5

7.9 ± 0.4 *

Soleus (mg)

8.7 ± 0.4

8.1 ± 0.3

7.9 ± 0.3

7.7 ± 0.4

7.4 ± 0.3

Plantaris (mg)

18.4 ± 0.5

17.7 ± 0.4

17.9 ± 0.6

16.4 ± 0.7

15.3 ± 0.6 *

Spleen (mg)

81.1 ± 6.1

76.6 ± 2.9

79.6 ± 3.5

238.7 ± 42.9 *#

391.5 ± 37.4 *#

Epi Fat (mg)

360.3 ± 19.4

368.2 ± 39.2

348.7 ± 15.7

237.6 ± 42.1 *#

252.3 ± 28.9 *#
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Figure 2:
week1 - pbs

week2 - pbs

week3 - pbs

week4 - pbs

week2 - week1

week3 - week1

week4 - week1

week3 - week2

week4 - week2

week4 - week3

Table 2:

pbs
pbs

wk1

wk2

wk3

wk4

1

9

18

993

0

99

1024

1

961

wk1

3

wk2

9

0

wk3

0

2

0

wk4

932

568

720

178
80
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Figure 3:
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Supplemental Figure 1:
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Figure 5:

Table 3:
Group
Wk 1 to PBS
Wk 2 to PBS
Wk 3 to PBS
Wk 4 to PBS
Wk 2 to Wk 1
Wk 3 to Wk 2
Wk 3 to Wk 1
Wk 4 to Wk 1
Wk 4 to Wk 2
Wk 4 to Wk 3

Identified % of
Genes
MitoCarta
0
0%
4
0.3%
0
0%
340
29.3%
0
0%
0
0%
3
0.3%
213
18.4%
255
22.0%
20
1.7%
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Figure 6:
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Appendix
Institutional Animal Care and Use Committee Approval

MEMORANDUM

TO:

Nicholas Greene

FROM:

Craig N. Coon, Chairman

DATE:

7/13/15

SUBJECT:

IACUC Approval

Expiration Date: Jan 1, 2018
The Institutional Animal Care and Use Committee (IACUC) has APPROVED your
protocol 15065: "Mitochondrial Degeneration in the Onset of Cancer-Cachexia
Induced Muscle Atrophy" you may begin work immediately
In granting its approval, the IACUC has approved only the information provided. Should
there be any further changes to the protocol during the research, please notify the IACUC
in writing (via the Modification form) prior to initiating the changes. If the study period is
expected to extend beyond Jan 1, 2018 you must submit a newly drafted protocol
prior to that date to avoid any interruption. By policy the IACUC cannot approve a study for
more than 3 years at a time.
The IACUC appreciates your cooperation in complying with University and Federal
guidelines involving animal subjects.

CNC/aem
cc: Animal Welfare Veterinarian
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